Heba Abdelazeem, Ly Tu, Raphaël Thuillet, Mina Ottaviani, Achraf Boulfrad, Thomas Beck, Amira Senbel, Salma Mani, Yves Castier, Alice Guyard, Alexy Tran-Dinh, Jamel El-Benna, Dan Longrois, Adam M Silverstein, Christophe Guignabert, Xavier Norel
Pulmonary hypertension (PH) is associated with pulmonary vasoconstriction and endothelial dysfunction leading to impaired nitric oxide (NO) and prostacyclin (PGI2 ) pathways. Metformin, the first line treatment for type 2 diabetes and AMP-activated protein kinase (AMPK) activator, has been recently highlighted as a potential PH treatment. AMPK activation has been reported to improve endothelial function by enhancing endothelial NO synthase (eNOS) activity and to have relaxant effects in blood vessels. In this study, we examined the effect of metformin treatment on PH as well as on NO and PGI2 pathways in monocrotaline (MCT)-injected rats with established PH...
March 11, 2023: European Journal of Pharmacology